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1. Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin damage the small
intestine as well as the stomach, although the ulcerogenic dose is much lower in the former
[1-3]. Several factors such as intestinal hypermotility, enterobacteria, neutrophils, nitric oxide
(NO), and inducible NO synthase (iNOS) are involved in the pathogenesis of these intestinal
lesions [3-7], yet a deficiency of endogenous prostaglandins (PGs) due to cyclooxygenase
(COX) inhibition is most important in the background for the intestinal ulcerogenic response
to NSAIDs [8-10]. Recent clinical studies, using capsule endoscopes or double-balloon
endoscopes, confirmed that NSAIDs damage the small intestine in patients at a higher
incidence than previously thought. Unfortunately, antisecretory drugs such as proton pump
inhibitors and histamine H2 receptor antagonists are reported to be ineffective against NSAID-
induced small intestinal damage [11,12] and even worsen the severity of these lesions [12],
though these drugs prevent gastric ulcerogenic response to NSAIDs [13].
Capsaicin-sensitive sensory neurons are known to play an important role in modulating the
gastric mucosal integrity [14]. It has previously been reported that stimulation of these sensory
neurons by capsaicin prevented the occurrence of experimental colitis as well as indomethacin-
induced intestinal ulceration in rats, while sensory deafferentation increased both the degree
and incidence of the latter lesion model [11,15,16]. These findings suggest the role of capsaicin-
sensitive sensory neurons in maintaining the integrity of the intestinal mucosa, similar to the
gastric mucosa.
Lafutidine, a histamine H2-receptor antagonist, has been shown to exhibit a potent gastropro‐
tective activity in addition to gastric antisecretory action [17,18]. Onodera et al. [19] reported
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that the gastroprotective action of lafutidine was independent of its antisecretory effect and
partially mediated by capsaicin-sensitive sensory neurons.
In the present report, we described the protective effect of lafutidine against NSAID-induced
enteropathy and suggested the involvement of capsaicin-sensitive afferent neurons in this
action.
2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats (240~280 g; Nippon Charles River, Shizuoka, Japan) were used.
Studies were carried out using four to eight animals without fasting in a conscious state, unless
otherwise specified. All experimental procedures described here were approved by the
Experimental Animal Research Committee of Kyoto Pharmaceutical University.
2.2. Induction of small intestinal lesions
Animals were given loxoprofen (60 mg/kg, p.o.) and killed 24 h later under deep ether
anesthesia. The small intestine was excised, treated with 2% formalin for fixation of the tissue
wall for 10 min and opened along the antimesenteric attachment. The area of macroscopically
visible damage (mm2) was measured under a dissecting microscope with square grids (x10),
summed per tissue and used as a lesion score. Lafutidine (10 and 30 mg/kg), cimetidine (100
mg/kg) or famotidine (30 mg/kg) was given p.o. twice, 0.5 h before and 6 h after the adminis‐
tration of loxoprofen, while omeprazole (100 mg/kg) was given p.o. once, 0.5 h before loxo‐
profen. On the other hand, ablation of capsaicin-sensitive sensory neurons was performed by
s.c. injection of capsaicin once daily for 3 consecutive days (total dose 100 mg/kg) 2 weeks
before the experiment [20]. All capsaicin injections were done under ether anesthesia, and the
rats were pretreated with terbutaline (0.1 mg/kg, i.m.) and aminophylline (10 mg/kg, i.m.) to
prevent respiratory impairment. The effectiveness of the treatment was tested by examining
the protective wiping movements of the eye.
2.3. Determination of enterobacterial counts
Enterobacteria were enumerated according to a method described by Deitch et al. [21]. Twenty-
four hours after loxoprofen treatment (60 mg/kg, p.o.), the animals were killed under deep
diethyl ether anesthesia, and the small intestines were excised. Aliquots of the homogenate of
intestine were placed on blood agar and Gifu anaerobic medium agar (Nissui, Tokyo, Japan).
Blood agar plates were incubated at 37°C for 24 h under aerobic conditions, whereas Gifu
anaerobic medium agar plates were incubated for 24 h under standard anaerobic conditions
(BBL Gas Pack Pouch Anaerobic System; BD Biosciences, San Jose, CA). Plates containing 10
to 300 colony-forming units (CFU) were examined for numbers of enterobacteria, and the data
were expressed as log CFU per gram of tissue. Lafutidine (10 and 30 mg/kg) was given p.o.
twice, 0.5 h before and 6 h after the administration of loxoprofen.
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2.4. Determination of iNOS and Muc2 mRNA Expression by RT-PCR
Expression of iNOS and Muc2 mRNA in the small intestinal mucosa was measured by RT-
PCR. The animals were killed under deep ether anesthesia 6 h after the administration of
loxoprofen, and the small intestines were removed, frozen in acetone/dryice, and stored
at-80°C prior to use. Tissue samples were pooled from 2 to 3 rats for extraction of total RNA,
which was prepared by a single-step acid phenol-chloroform extraction procedure by use of
Sepasol RNA-I (Nacalai Tesque, Kyoto, Japan). Total RNA primed by random hexadeoxy
ribonucleotide was reverse-transcribed with the Rever Tra Ace-a (Toyobo, Osaka, Japan). An
aliquot of the RT reaction product served as a template in 35 cycles of PCR with 0.5 min of
denaturation at 95°C and 1 min of extension at 68°C by Advantage-2 (BD Biosciences, Palo
Alto, CA, USA) on a thermal cycler (PC806; ASTEC, Fukuoka, Japan). A portion of the PCR
mixture was electrophoresed in 1.8% agarose gel in TAE buffer, and the gel was stained with
ethidium bromide and photographed (Bio Doc-It Imaging System; UVP, Upland, CA, USA).
Lafutidine (30 mg/kg) was given p.o. twice, 0.5 h before and 6 h after the administration of
loxoprofen.
2.5. Determination of mucus secretion in small intestine
The amount of mucus secreted in the small intestine was determined by periodic acid-Schiff
(PAS) staining. Three hours after the administration of loxoprofen (60 mg/kg, p.o.), the animals
were killed under deep diethyl ether anesthesia, and the small intestines were removed. The
removed tissues were fixed in Carnoy's fluid (ethanol : acetic acid : chloroform=6 : 1 : 3) for 24
h, embedded in paraffin, and sectioned at a thickness of 6 µm. PAS staining was subsequently
performed according to the conventional method. Lafutidine (30 mg/kg) was given p.o. with
or without co-administration of loxoprofen. In the combined administration, this agent was
given p.o. 30 min before the administration of loxoprofen.
2.6. Preparation of drugs
The drugs used were lafutidine, cimetidine, famotidine, loxoprofen, ampicillin (Shigma
Chemicals, St. Louis, MO), and omeprazole. Lafutidine, cimetidine, famotidine, omeprazole
or loxoprofen was suspended in a 0.5% hydroxy propyl cellulose solution (Wako). All drugs
were prepared immediately before use and administered p.o. or s.c. in a volume of 0.5 ml/100
g body weight. Control animals received the vehicle alone.
2.7. Statistics
Data are presented as the mean±SE for four to eight rats per group. Statistical analyses were
performed using the two-tailed Dunnett’s multiple comparison test, and values of P<0.05 were
considered significant.




3.1. Effect of anti-secretory drugs on loxoprofen-induced small intestinal lesions
Orally administered loxoprofen (10-100 mg/kg) in normally fed rats dose-dependently
produced multiple hemorrhagic lesions in the small intestine, mainly in the jejunum and ileum.
The severity of these lesions induced by loxoprofen at 60 mg/kg was similar to that of the
lesions produced by indomethacin at 10 mg/kg. When animals were pretreated with lafutidine
(10 and 30 mg/kg) given p.o., this treatment dose-dependently prevented the development of
intestinal lesions in response to loxoprofen (60 mg/kg), and the effect was significant at 30 mg/
kg; the inhibition rate was around 50 % (Figure 1). By contrast, neither cimetidine (100 mg/kg)
nor famotidine (30 mg/kg), given p.o., had significant effect on the intestinal ulcerogenic
response to loxoprofen. Similarly, omeprazole (100 mg/kg, p.o.) did not affect the severity of
loxoprofen-induced intestinal lesions.
Figure 1. Effects of various agents on the intestinal lesions induced by loxoprofen in rats. Animals were given loxopro‐
fen (60 mg/kg) p.o. and killed 24 h later. Lafutidine (10 and 30 mg/kg), cimetidine (100 mg/kg) or famotidine (30
mg/kg) was given p.o. twice, 30 min before and 6 h after administration of loxoprofen, while omeprazole (100
mg/kg) was given p.o. once, 30 min before. Data are presented as the mean±SE from 5~8 rats. *Significant difference
from the corresponding control, at P<0.05. Data adapted after modification of ref. [26].
On the other hand, the severity of intestinal lesions induced by loxoprofen was significantly
aggravated by chemical ablation of capsaicin-sensitive sensory neurons, about 1.4 times
greater than the capsaicin nontreated animals (Figure 2). Lafutidine (30 mg/kg, p.o.) again
significantly suppressed the intestinal ulcerogenic response to loxoprofen, but this effect was
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside200
totally attenuated by sensory deafferentation, the lesion score was almost equivalent to the
control value in the sensory deafferented animals.
Figure 2. Effect of lafutidine on the intestinal lesions induced by loxoprofen in normal and sensory deafferented rats.
Animals were given loxoprofen (60 mg/kg) p.o. and killed 24 h later. Sensory deafferentation was performed by 3
consecutive s.c. injections of capsaicin (total 100 mg/kg) 2 weeks before the experiment. Lafutidine (30 mg/kg) was
given p.o. twice, 30 min before and 6 h after loxoprofen. Data are presented as the mean±SE from 6~7 rats. *Signifi‐
cant difference from control in normal rats, at P<0.05. Data adapted after modification of ref. [26].
3.2. Effect of lafutidine on mucosal invasion of enterobacteria caused by loxoprofen
Following oral administration of loxoprofen (60 mg/kg), the bacterial counts in both aerobic
and anaerobic conditions were markedly increased compared to normal group, 24 h later
(Table 1). Pretreatment of the animals with lafutidine (30 mg/kg) significantly prevented
bacterial invasion in the mucosa following the administration of loxoprofen. The mucosal
invasion of enterobacteria was also increased after loxoprofen treatment in sensory deaffer‐
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ented animals. The inhibitory effect of lafutidine on bacterial invasion was totally attenuated
in the animals with sensory deafferentation.
The animals were given loxoprofen (60 mg/kg, p.o.) and killed 24 h later. Lafutidine (30
mg/kg, p.o.) was given twice, 30 min before and 6 hr after the administration of sodium
loxoprofen. Data are presented as the mean±SE from 4~5 rats. Significant difference at
P<0.05; a) from the corresponding control, b) from loxoprofen in the normal group. Data
adapted after modification of ref. [26].
Table 1. Effect of Lafutidine on Bacterial Counts in Rat Small Intestine
3.3. Changes in mucosal expression of iNOS and Muc2 mRNA
The iNOS mRNA expression  was  hardly  detected  in  the  normal  intestinal  mucosa,  but
markedly  up-regulated  after  the  administration  of  loxoprofen  (60  mg/kg,  p.o.)  when
examined 6 h later (Figure 3a). The up-regulation of iNOS expression following loxopro‐
fen was markedly suppressed by pretreatment of the animals with lafutidine (30 mg/kg).
Loxoprofen (60 mg/kg) similarly increased iNOS mRNA expression in sensory deafferent‐
ed animals.  In these animals,  however,  lafutidine did not  affect  the expression of  iNOS
mRNA in the small intestinal mucosa.
On the other hand, the expression of Muc2 mRNA was clearly detected in the normal intestinal
mucosa, but apparently down-regulated after the administration of loxoprofen (60 mg/kg)
when examined 6 h later (Figure 3b). The decrease in Muc2 expression caused by loxoprofen
was almost totally reverted by pretreatment of lafutidine (30 mg/kg), but this effect was not
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observed in the animals with sensory deafferentation, similar to the inhibitory effect on the
iNOS expression.
Figure 3. Effect of lafutidine on the expression of iNOS and Muc2 mRNAs in rat small intestine. Animals were given
loxoprofen (60 mg/kg) p.o. and killed 6 h later. Sensory deafferentation was performed by 3 consecutive s.c. injections
of capsaicin (total 100 mg/kg) 2 weeks before the experiment. Lafutidine (30 mg/kg) was given p.o. 30 min before the
administration of loxoprofen. Data adapted after modification of ref. [26].
3.4. Effect of Lafutidine on PAS-Positive Substances in Small Intestine
In the normal intestinal mucosa, PAS-positive substances were observed over the surface
epithelial cells and along the glands (Figure 4A). Loxoprofen (60 mg/kg, p.o.) apparently
reduced the amount of PAS-positive substances in the epithelial cells as well as the glands
(Figure 4B). However, the reduction in PAS staining was markedly restored when lafutidine
(30 mg/kg) was administered prior to loxoprofen treatment (Figure 4C). In addition, lafutidine
by itself increased the amount of PAS-positive substances in the mucosa compared to the
control mucosa (Figure 4D).
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Figure 4. Microscopic observations of the rat small intestinal mucosa. The animals were given loxoprofen (60 mg/kg)
p.o. and killed 3 h later. Lafutidine (30 mg/kg) was given p.o. 30 min before the administration of loxoprofen. Figures
show; a: normal; b: loxoprofen alone; c: lafutidine plus loxoprofen; d: lafutidine alone. (PAS; x100). Data adapted after
modification of ref. [26].
4. Commentary
The present study demonstrated that oral administration of loxoprofen induced multiple
hemorrhagic lesions in the small intestine, similar to indomethacin [5], and that lafutidine
protected these intestinal lesions, mediated by capsaicin-sensitive sensory neurons.
We confirmed that loxoprofen produced hemorrhagic lesions in the small intestine, and the
severity of these lesions at 60 mg/kg was almost equivalent to that of the lesions generated by
indomethacin. The onset of these lesions was accompanied by the mucosal invasion of
enterobacteria and the up-regulation of iNOS expression, those events being similarly
observed after indomethacin treatment. We also confirmed that the ulcerogenic response
induced by loxoprofen in the small intestine was significantly prevented by pretreatment of
the animals with dmPGE2 as a supplement for PG deficiency or ampicillin as an antibiotic, the
same was reported using the intestinal indomethacin-induced intestinal lesions [3-5].
Capsaicin - Sensitive Neural Afferentation and the Gastrointestinal Tract: from Bench to Bedside204
Lafutidine is a histamine H2-receptor antagonist with both antisecretory and gastroprotective
action [17,18]. Onodera et al. [19] reported that the mucosal protective action of lafutidine was
mediated by capsaicin-sensitive sensory neurons and independent of the antisecretory
activity, because the action was not mimicked by cimetidine, another H2-receptor antagonist,
and was totally abolished by chemical deafferentation of sensory neurons. In the present study
we observed that lafutidine protected the small intestine from loxoprofen-induced intestinal
lesions. Certainly, this effect is not brought about by inhibition of gastric acid secretion, since
omeprazole, an inhibitor of H+/K+ATPase, had no effect on this lesion model, similar to
cimetidine. These drugs at the doses used (100 mg/kg) reportedly caused nearly a complete
inhibition of acid secretion [22,23], supporting the idea that acid does not participate in the
pathogenesis of loxoprofen-induced small intestinal lesions.
Lafutidine has been previously shown to prevent indomethacin-induced enteropathy and this
effect was significantly attenuated by chemical ablation of capsaicin-sensitive sensory neurons
[11]. Consistent with these findings, we found that lafutidine dose-dependently reduced the
severity of intestinal lesions produced by loxoprofen and this action disappeared in the animals
with sensory deafferentation. The peptidergic afferent innervation of the intestine has been
demonstrated in various species of animals including the rat [14,24,25]. Several studies have
demonstrated that stimulation of sensory neurons by capsaicin significantly prevented the
occurrence of colitis as well as intestinal ulceration induced experimentally in rats [15,16]. We
also noted that the ulcerogenic response to loxoprofen in the rat intestine was significantly
aggravated by ablation of these sensory neurons. These results together with previous studies
[11,15,16] strongly suggest that capsaicin-sensitive sensory neurons play a role in maintaining
the mucosal integrity of the intestine against noxious stimuli, similarly in the stomach.
The intestinal ulcerogenic response to loxoprofen was also markedly suppressed by prior
administration of ampicillin, an antibiotics, similar to that induced by indomethacin [26]. These
findings were supported by the fact that NSAID-induced small intestinal lesions do not occur
in germ-free animals or fasting animals [5,27], suggesting a major pathogenic role for entero‐
bacteria in these lesions. Because lafutidine significantly mitigated the bacterial invasion in the
mucosa after loxoprofen treatment, this effect may account, at least partly, for the prophylactic
effect of this agent against the intestinal lesions produced by loxoprofen. As mentioned earlier,
the protective effect of lafutidine was almost totally attenuated by sensory deafferentation
following capsaicin pretreatment. We also found in the present study that the suppression by
lafutidine of the enterobacterial invasion following loxoprofen treatment was not observed in
the sensory deafferented animals. Since mucus plays an important part in the innate host
defense against intestinal pathogens and irritants, it is possible that a decreased mucus
production/ secretion plays a role in the pathogenic mechanism of NSAID-induced intestinal
damage by accelerating bacterial invasion in the mucosa. We have previously reported that
indomethacin at an ulcerogenic dose reduced the amount of mucus secreted in the small
intestine, in a PGE2-sensitive manner, and this effect preceded bacterial invasion [10]. Lafuti‐
dine increased mucus secretion in the stomach, at least partly mediated by capsaicin-sensitive
sensory neurons [28,29]. We observed in the present study that lafutidine by itself markedly
increased levels of PAS-positive materials in the intestinal mucosa and reverted the reduced
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response to loxoprofen. Furthermore, it was found that lafutidine increased the expression of
Muc2 mRNA in the small intestine and this response was totally mitigated by ablation of
capsaicin-sensitive sensory neurons. Muc2, one of important mucin genes, plays an important
role in the dimerization of secretory mucins, an essential step in the formation of the gastro‐
intestinal mucus-gels [30]. It is possible that lafutidine up-regulates Muc2 expression and
mucus secretion through a sensory neuron-dependent mechanism and thereby increases the
mucus gel thickness and hampers enterobacterial invasion in the mucosa.
Lafutidine prevented the up-regulation of iNOS expression in the small intestine, an important
event in the occurrence of intestinal lesions caused by NSAIDs [2,31]. Boughton-Smith et al.
[32] reported that bacterial endotoxin from E. coli enhanced the intestinal permeability though
up-regulation of iNOS and overproduction of NO in the mucosa. Since lafutidine was found
to prevent bacterial invasion, probably by up-regulating Muc2/mucus expression, it would be
understandable that this agent suppressed the increase of iNOS expression in the small
intestine following loxoprofen treatment. We previously reported that the mucosal protective
drugs, such as irsogladine, rebamipide and teprenone, all significantly increased mucus
secretion and suppressed bacterial invasion and iNOS expression, thereby reduced the severity
of intestinal lesions produced by indomethacin [33]. These results together support a cause-
effect relationship between changes in the above three events; ie., mucus secretion, bacterial
invasion, and iNOS expression.
5. Summary
Lafutidine protects the small intestine against loxoprofen-induced lesions. This effect is not
associated with inhibition of acid secretion due to the blockade of histamine H2-receptors and
appears to be mediated by capsaicin-sensitive sensory neurons. The exact mechanism under‐
lying the intestinal protection by lafutidine remains unknown, yet it is assumed that lafutidine
prevents the process of enterobacterial invasion in the mucosa by increasing the mucus gel
layer through the up-regulation of Muc2 mRNA expression, and thereby suppresses iNOS
induction, resulting in prevention of the occurrence of intestinal lesions following loxoprofen
treatment.
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